

40. (New) A transformant comprising the recombinant DNA of claim 7.

REMARKS

The claims have been amended to correct their dependency and conformity with accepted U.S. practice. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

6. (Amended) A recombinant DNA obtained by inserting the DNA of [any one of] claim[s] 3 [to 5] into a vector.

8. (Amended) A transformant comprising the recombinant DNA of claim 6 [or 7].

12. (Amended) A method for producing the polypeptide [of claim 1 or 2,] comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:10 to 16, or comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:14 to 16 and is capable of binding to JNK3, comprising culturing the transformant of [any one of] claim[s] 8 [to 11] in a medium to produce and accumulate the

polypeptide [of claim 1 or 2] in the culture, and recovering the polypeptide from the culture.

13. (Amended) An oligonucleotide which is selected from an oligonucleotide comprising a sequence identical to continuous 5 to 60 bases in a nucleotide sequence in [any one of the DNA's of] claim[s] 3 [to 5] and the DNA comprising the nucleotide sequence represented by SEQ ID NO:5, an oligonucleotide comprising a sequence complementary to the oligonucleotide, and an oligonucleotide analogue of these oligonucleotides.

15. (Amended) A method for detecting mRNA encoding the polypeptide [of claim 1 or 2,] comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:10 to 16, or comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:14 to 16 and is capable of binding to JNK3, comprising using the oligonucleotide of claim 13 or 14.

16. (Amended) A method for inhibiting expression of the polypeptide [of claim 1 or 2,] comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:10 to 16, or comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:14 to 16 and is capable of binding to JNK3, comprising using the oligonucleotide of claim 13 or 14.

18. (Amended) A method for immunologically detecting the polypeptide [of claim 1 or 2,] comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:10 to 16, or comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:14 to 16 and is capable of binding to JNK3, comprising using the antibody of claim 17.

19. (Amended) A method for immunohistologically staining of the polypeptide [of claim 1 or 2,] comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:10 to 16, or comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:14 to 16 and is capable of binding to JNK3, comprising using the antibody of claim 17.

25. (Amended) The method [according to claim 24] of screening a compound capable of changing expression of a gene encoding a polypeptide, comprising bringing a cell which expresses the polypeptide into contact with a test sample, said polypeptide comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:9 to 16 or a polypeptide comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by SEQ ID NOS:9 to 16

and being capable of binding to JNK3, wherein the expression of a gene is detected by the method of claim 15.

26. (Amended) The method [according to claim 24] of screening a compound capable of changing expression of a gene encoding a polypeptide, comprising bringing a cell which expresses the polypeptide into contact with a test sample, said polypeptide comprising an amino acid sequence selected from the amino acid sequences represented by any one of SEQ ID NOS:9 to 16 or a polypeptide comprising an amino acid sequence in which at least one amino acid has been deleted, substituted or added in an amino acid sequence selected from the amino acid sequences represented by SEQ ID NOS:9 to 16 and being capable of binding to JNK3, wherein the polypeptide is detected using the method of claim 18.

27. (Amended) A compound obtained by the method of [any one of] claim[s] 24 [to 26] or a pharmacologically acceptable salt thereof.

30. (Amended) An agent for preventing neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or [various] immunological and inflammatory diseases, comprising the polypeptide of claim 1 or 2.

31. (Amended) An agent for treating neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or [various] immunological and inflammatory diseases, comprising the polypeptide of claim 1 or 2.

32. (Amended) An agent for preventing neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis

and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or [various] immunological and inflammatory diseases, comprising the oligonucleotide of claim 13 [or 14].

33. (Amended) An agent for treating neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or [various] immunological and inflammatory diseases, comprising the oligonucleotide of claim 13 [or 14].

34. (Amended) An agent for preventing neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or

[various] immunological and inflammatory diseases, comprising the antibody of claim 17.

35. (Amended) An agent for treating neurodegenerative diseases, [such as Alzheimer's disease, Parkinson's disease, Huntington disease, multiple sclerosis and the like,] amyotrophic diseases, [such as amyotrophic lateral sclerosis and the like,] ischemic diseases, brain damage due to stroke, schizophrenia, depression, epilepsy, or [various] immunological and inflammatory diseases, comprising the antibody of claim 17.

NY_MAIN 171455 v 1